Pictet Asset Management Holding SA Sells 156,247 Shares of Moderna, Inc. $MRNA

Pictet Asset Management Holding SA reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 25.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 446,265 shares of the company’s stock after selling 156,247 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.11% of Moderna worth $89,131,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Costello Asset Management INC boosted its holdings in Moderna by 7.3% in the 3rd quarter. Costello Asset Management INC now owns 966 shares of the company’s stock worth $186,000 after buying an additional 66 shares during the period. Physician Wealth Advisors Inc. increased its stake in Moderna by 8.3% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 886 shares of the company’s stock worth $171,000 after buying an additional 68 shares in the last quarter. Fortitude Family Office LLC raised its holdings in Moderna by 53.1% during the third quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock valued at $43,000 after acquiring an additional 77 shares during the period. TD Waterhouse Canada Inc. raised its holdings in Moderna by 2.6% during the second quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock valued at $246,000 after acquiring an additional 85 shares during the period. Finally, SteelPeak Wealth LLC raised its holdings in Moderna by 3.9% during the third quarter. SteelPeak Wealth LLC now owns 3,397 shares of the company’s stock valued at $654,000 after acquiring an additional 127 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

NASDAQ:MRNA opened at $269.00 on Tuesday. The firm has a market capitalization of $107.40 billion, a price-to-earnings ratio of -37.89 and a beta of 1.16. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The business has a 50 day simple moving average of $194.47 and a 200-day simple moving average of $92.61. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $280.80.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($1.10) by $1.48. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $890.25 million. During the same quarter in the previous year, the company posted ($0.51) EPS. The company’s revenue for the quarter was up 29.2% compared to the same quarter last year. Equities analysts forecast that Moderna, Inc. will post -6.11 EPS for the current year.

Insiders Place Their Bets

In other news, insider Shannon Klinger sold 3,471 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares of the company’s stock, valued at $7,985,343.75. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 197,251 shares of company stock valued at $33,875,904 over the last three months. 10.80% of the stock is owned by company insiders.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Raised outlook and improved results: Moderna lifted its 2026 revenue-growth forecast to 15%–25% after a Q3 beat, citing lower costs and gains from respiratory vaccines. Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology
• Positive Sentiment: Oncology pipeline milestone: Phase 3 data for personalized cancer therapy intismeran showed a 42% reduction in melanoma recurrence or death risk. Moderna aims to file with the FDA by year-end 2026, potentially setting up a decision in 2027. Can Moderna’s First Cancer Therapy Win FDA Approval in 2027?
• Positive Sentiment: Moderna’s collaboration with Tempus AI is among partnerships expected to generate about $192.5 million over five years, adding a potential source of revenue beyond vaccine sales. The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
• Neutral Sentiment: Analysts raised one fair-value estimate from $135.84 to $145.42, reflecting improved Q3 execution and intismeran’s potential, while noting uncertainty about future COVID and oncology revenue. Moderna Stock Fair Value Rises After Intismeran Data And Q3 Beat
• Negative Sentiment: Revenue concentration and valuation risk: Nearly all revenue still comes from COVID-related products, leaving Moderna exposed to demand changes. Goldman Sachs raised its target to $195 but kept a neutral rating; that target and the cited fair-value estimate are both below the $269 price in the provided market data. Moderna’s Q3 Numbers May Have Seemed Impressive, but They Aren’t Enough to Make the Stock a Buy

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price objective on Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research report on Friday, August 21st. Piper Sandler reissued an “overweight” rating and set a $305.00 target price (up from $230.00) on shares of Moderna in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Moderna in a research report on Wednesday, September 9th. Rothschild & Co Redburn lowered Moderna from a “neutral” rating to a “sell” rating and raised their price objective for the company from $40.00 to $81.00 in a research report on Thursday, September 3rd. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Moderna in a report on Friday, August 28th. They set a “hold” rating and a $125.00 price target for the company. Six investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat.com, Moderna has an average rating of “Hold” and an average target price of $113.75.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.